

Recaticimab

Cat. No.:	HY-P99822
CAS No.:	2361290-85-7
Target:	Ser/Thr Protease
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Recaticimab mediates the degradation of PCSK9 by binding to PCSK9, increasing the level of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, reducing the level of LDL in plasma, and achieving the goal of lowering blood lipids. Recaticimab has potential application in hypercholesterolemia^{[1][2]}.

REFERENCES

[1]. Xu M, et al. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study. BMC Med. 2022 Jan 18;20(1):13.

[2]. Jiao J, et al. Pharmaceutical composition of pcsk9 inhibitor and glp-1 receptor agonist. World Intellectual Property Organization. WO2022268214.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA